A 45% reduction in the risk of disease progression or death is a striking number for a population that has already burned through at least one covalent BTK inhibitor, and that is exactly the population BRUIN CLL-322 was designed to reflect. Eli Lilly announced Phase 3 results showing that adding pirtobrutinib to a two-year venetoclax plus rituximab backbone produced a hazard ratio of 0.55 (95% CI, 0.40–0.75; p=0.0001) in relapsed or refractory CLL/SLL, with median PFS in the triplet arm not yet reached against 39.7 months in the doublet arm at a median follow-up of 27.3 months. The data will be presented as a late-breaking oral at the 2026 European Hematology Association meeting in Stockholm.
The design choice that matters most here is who was enrolled. Nearly 80% of the 639 patients had prior covalent BTK inhibitor exposure, meaning the control arm’s 39.7-month median PFS is not coming from a BTK-naive, favorable-biology group. That context sharpens the interpretation considerably. The most striking subset is the exploratory second-line cohort whose disease progressed after a first-line covalent BTK inhibitor: 24-month PFS rates of 88% versus 52% favoring the pirtobrutinib triplet, with an HR of 0.32. That is a small subgroup and carries all the usual caveats of unplanned analyses, but the magnitude is hard to dismiss. Lilly also reported that pirtobrutinib’s introduction allowed downgrading of tumor lysis syndrome risk in a meaningful proportion of high-risk patients, a practical clinical benefit that simplifies monitoring logistics. The time-to-next-treatment endpoint consistently favored the triplet as well (HR=0.50), which in a disease where treatment-free intervals matter to patients is a real outcome, not a surrogate artifact.
Pirtobrutinib received traditional FDA approval in December 2025 for relapsed or refractory CLL/SLL in patients previously treated with a covalent BTK inhibitor. BRUIN CLL-322 is now the Phase 3 randomized evidence base for a label expansion into combination use, and Lilly has stated its intent to file with global regulators. The safety picture was broadly manageable: Grade 3 or higher adverse events ran at 78.8% in the triplet versus 73.0% in the doublet, discontinuation rates due to treatment-related adverse events were nearly identical across arms (5.4% versus 5.1%), and rates of atrial fibrillation remained low. Overall survival data are immature, with an HR of 0.89 that is nowhere near significance, so the question of whether the PFS gain translates to a survival benefit remains genuinely open.
The single number to track now is the OS readout at the planned final analysis. BRUIN CLL-322’s primary endpoint is secured, but regulators and payers will want to see whether extending remission duration in this heavily pretreated population eventually bends the survival curve. If it does, the triplet’s claim to a new standard of care in post-covalent BTK inhibitor relapse becomes substantially harder to argue against.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
